Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CEO Yvonne Greenstreet Sells 31,640 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) CEO Yvonne Greenstreet sold 31,640 shares of the firm's stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $304.39, for a total value of $9,630,899.60. Following the completion of the sale, the chief executive officer now directly owns 48,948 shares in the company, valued at $14,899,281.72. This trade represents a 39.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Yvonne Greenstreet also recently made the following trade(s):

• On Monday, June 2nd, Yvonne Greenstreet sold 19,297 shares of Alnylam Pharmaceuticals stock. The stock was sold at an average price of $306.00, for a total transaction of $5,904,882.00.

Alnylam Pharmaceuticals Trading Down 1.6%

ALNY stock traded down $5.03 on Friday, hitting $302.97. 385,875 shares of the company were exchanged, compared to its average volume of 927,993. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The stock has a market capitalization of $39.50 billion, a price-to-earnings ratio of -139.85 and a beta of 0.17. Alnylam Pharmaceuticals, Inc. has a twelve month low of $147.25 and a twelve month high of $310.58. The business's fifty day moving average is $263.27 and its two-hundred day moving average is $256.68.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The business had revenue of $594.19 million for the quarter, compared to the consensus estimate of $584.32 million. During the same period in the prior year, the company posted ($0.16) EPS. The firm's revenue for the quarter was up 20.2% compared to the same quarter last year. As a group, research analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ALNY. Citigroup raised their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a "buy" rating in a research note on Friday, March 21st. HC Wainwright reiterated a "buy" rating and issued a $500.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Scotiabank lifted their price target on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a "sector outperform" rating in a report on Monday, March 31st. Redburn Atlantic assumed coverage on Alnylam Pharmaceuticals in a research note on Monday, March 31st. They issued a "buy" rating and a $353.00 price objective on the stock. Finally, William Blair reissued an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and twenty-two have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $319.17.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Institutional investors have recently modified their holdings of the stock. Capital World Investors boosted its holdings in Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Capital World Investors now owns 16,600,525 shares of the biopharmaceutical company's stock worth $3,906,284,000 after purchasing an additional 92,101 shares during the period. Vanguard Group Inc. grew its position in shares of Alnylam Pharmaceuticals by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 13,056,605 shares of the biopharmaceutical company's stock valued at $3,525,544,000 after buying an additional 323,206 shares during the last quarter. Capital Research Global Investors raised its stake in Alnylam Pharmaceuticals by 32.9% during the fourth quarter. Capital Research Global Investors now owns 6,968,513 shares of the biopharmaceutical company's stock worth $1,639,767,000 after acquiring an additional 1,724,610 shares during the period. Regeneron Pharmaceuticals Inc. bought a new position in Alnylam Pharmaceuticals in the fourth quarter worth about $1,045,822,000. Finally, T. Rowe Price Investment Management Inc. boosted its stake in Alnylam Pharmaceuticals by 0.8% in the first quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock valued at $1,192,988,000 after acquiring an additional 33,696 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.